iollo.com

What It Is

iollo is an “AI meets biology” platform founded by Stanford scientists and backed by Y Combinator. Its website presents two business lines: Quinn, an enterprise product for biomedical R&D, and a consumer-facing blood metabolomics test designed to help users understand inflammation, energy, aging, gut health, cardiovascular status, and more.

Core Capabilities and Use Cases

Quinn is described as “The AI Scientist,” covering stages of biomedical R&D from Target ID, Hit-to-Lead, Lead Optimization, and IND-enabling through to Clinical. Its goal is to unify computational R&D while providing complete analysis pipelines and transparent reasoning. A key selling point is that it “Runs entirely in your environment” and emphasizes “Your cloud • Your data,” making it suitable for pharmaceutical or biotech companies with strict requirements around data isolation and compliance. The consumer product focuses on clinical-grade at-home collection, measuring 600+ metabolites from a single blood sample and supporting longitudinal tracking over time.

Pricing, Trials, and Integrations

The main site does not disclose any specific pricing, plans, free quotas, or trial policies. Quinn is labeled Enterprise and offers a “Schedule a demo” option, suggesting sales-led engagement and customized deployment. Integrations such as APIs, SDKs, ELN/LIMS, or data warehouses are not mentioned; the only confirmed point is that the enterprise product can run in the customer’s own environment.

Data Privacy and Compliance

Privacy and compliance are among the clearer highlights on iollo’s pages. The enterprise offering is marked as SOC 2 Type II and emphasizes customer cloud and customer data; the consumer testing product is marked HIPAA compliant. These details are valuable for life sciences and health data use cases, but the site does not explain data retention periods, training data usage policies, cross-border transfer arrangements, or deletion mechanisms.

Pros, Cons, and Who It’s For

Its strengths are a clear positioning, coverage of key drug discovery and development workflows, and the combination of AI analysis with metabolomics testing. It also emphasizes transparent reasoning, deployment in the customer’s environment, and compliance. The limitations are also obvious: there are no public details on model architecture, validation results, case studies, pricing, Chinese-language support, or service regions. It is best suited to biomedical companies with the budget and need for customized computational R&D support, as well as health management or longevity medicine users who can access its testing service.

Access from China and Alternatives

The website does not provide information on China access, payment, logistics, or Chinese-language reports, so china_access can only be assessed as unknown. For use in China, enterprise customers should pay close attention to network accessibility, cross-border data transfer, contract compliance, invoicing, and payment methods. For consumer testing, users also need to confirm sample kit delivery, sample return logistics, and the applicability of the medical report.